Correction 03 June 2020: In the original version of this article, Timothy Yu’s comment that "academics are not well positioned to lead the charge for n-of-one therapies" is inaccurate. Yu thinks that academic medical centers will play a key role in developing n-of-one therapies, although they aren’t positioned to scale up yet. Also, the cost Yu mentions for oligonucleotide synthesis refers to research grade oligonucleotides, not clinical grade ones, which are more expensive. The text has been corrected to address these errors.